# Product Information
Keywords: Avonex, Benepali, Flixabi, Imraldi, Plegridy, Skyclarys, Spinraza, Tecfidera, Tysabri, Vumerity, ZURZUVAE, patient information leaflet, summary of product characteristics, European public assessment report, adverse effects reporting

> This page provides detailed product information for various medicines, including patient information leaflets, summaries of product characteristics, and European public assessment reports. It also includes guidance on reporting adverse effects.

## Details
- [Avonex (interferon beta-1a)](#): Links to patient information leaflets, product characteristics, and assessment reports for the UK and Ireland.
- [Benepali (etanercept)](#): Provides access to patient information leaflets and product characteristics for the UK and Ireland.
- [Flixabi (infliximab)](#): Includes patient information leaflets and product characteristics for the UK and Ireland.
- [Imraldi (adalimumab)](#): Offers patient information leaflets and product characteristics for the UK and Ireland.
- [Plegridy (peginterferon beta-1a)](#): Contains intramuscular and subcutaneous patient information leaflets and product characteristics for the UK and Ireland.
- [Skyclarys (omaveloxolone)](#): Features patient information leaflets and product characteristics, as well as an assessment report, for the UK and Ireland.
- [Spinraza (nusinersen sodium)](#): Details patient information leaflets and product characteristics for the UK and Ireland, along with an assessment report.
- [Tecfidera (dimethyl fumarate)](#): Provides patient information leaflets, product characteristics, and an assessment report for the UK and Ireland.
- [Tysabri (natalizumab)](#): Includes intravenous and subcutaneous patient information leaflets and product characteristics for the UK and Ireland.
- [Vumerity (diroximel fumarate)](#): Offers patient information leaflets, product characteristics, and an assessment report for the UK and Ireland.
- [ZURZUVAE (zuranolone)](#): Contains UK-only patient information leaflets and product characteristics for 20mg and 25mg dosages.
- [Reporting of side effects](#): Instructions for reporting adverse effects in the UK and Ireland, including contact details and links to national reporting systems.